Impact of bariatric surgery on cardiovascular outcomes and mortality: a population-based cohort study.
Journal
The British journal of surgery
ISSN: 1365-2168
Titre abrégé: Br J Surg
Pays: England
ID NLM: 0372553
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
25
06
2019
revised:
04
09
2019
accepted:
28
10
2019
pubmed:
23
1
2020
medline:
5
11
2020
entrez:
23
1
2020
Statut:
ppublish
Résumé
Cohort studies have shown that bariatric surgery may reduce the incidence of and mortality from cardiovascular disease (CVD), but studies using real-world data are limited. This study examined the impact of bariatric surgery on incident CVD, hypertension and atrial fibrillation, and all-cause mortality. A retrospective, matched, controlled cohort study of The Health Improvement Network primary care database (from 1 January 1990 to 31 January 2018) was performed (approximately 6 per cent of the UK population). Adults with a BMI of 30 kg/m A total of 5170 exposed and 9995 control participants were included; their mean(s.d.) age was 45·3(10·5) years and 21·5 per cent (3265 of 15 165 participants) had T2DM. Median follow-up was 3·9 (i.q.r. 1·8- 6·4) years. Mean(s.d.) percentage weight loss was 20·0(13·2) and 0·8(9·5) per cent in exposed and control groups respectively. Overall, bariatric surgery was not associated with a significantly lower CVD risk (adjusted hazard ratio (HR) 0·80; 95 per cent c.i. 0·62 to 1·02; P = 0·074). Only in the gastric bypass group was a significant impact on CVD observed (HR 0·53, 0·34 to 0·81; P = 0·003). Bariatric surgery was associated with significant reduction in all-cause mortality (adjusted HR 0·70, 0·55 to 0·89; P = 0·004), hypertension (adjusted HR 0·41, 0·34 to 0·50; P < 0·001) and heart failure (adjusted HR 0·57, 0·34 to 0·96; P = 0·033). Outcomes were similar in patients with and those without T2DM (exposed versus controls), except for incident atrial fibrillation, which was reduced in the T2DM group. Bariatric surgery is associated with a reduced risk of hypertension, heart failure and mortality, compared with routine care. Gastric bypass was associated with reduced risk of CVD compared to routine care. Estudios de cohortes han mostrado que la cirugía bariátrica puede reducir la incidencia de enfermedad cardiovascular (cardiovascular disease, CVD) y la mortalidad, pero los estudios basados en datos del mundo real son limitados. Este estudio examinaba el impacto de la cirugía bariátrica (bariatric surgery, BS) en la incidencia de CVD, hipertensión, fibrilación auricular (FA) y mortalidad por cualquier causa. MÉTODOS: Se realizó un estudio retrospectivo de cohortes, controlado por emparejamiento, a partir de la base de datos de atención primaria del The Health Improvement Network (THIN) (1/1/1990 y 31/1/2018) (aproximadamente el 6% de la población del Reino Unido UK). En el grupo de exposición, se incluyeron adultos con un índice de masa corporal (IMC) ≥ 30 kg/m Se incluyeron un total de 5.170 sujetos expuestos y 9.995 participantes controles. La edad media (DE) fue 45,3 (10,5) años, 21,5% (n = 3.265) tenían T2D. La mediana de seguimiento era de 3,9 años (rango intercuartílico 1,8- 6,4). La media ± desviación estándar del % de pérdida de peso fue del 20,0 ± 13,2% en el grupo BS versus 0,8 ± 9,5% en los grupos control. Globalmente, la BS no se asoció con una CVD significativamente más baja (cociente de riesgos instantáneos ajustados, adjusted hazard ratio, HR 0,80; i.c. del 0,62- 1,02, P = 0,074). Solo en el grupo del bypass gástrico se observó un impacto significativo en CVD (0,53, 0,34- 0,81, P = 0,003). BS se asoció con una reducción significativa en la mortalidad de cualquier causa (0,70; i.c. Del 95% 0,55- 0,89, P = 0,004), hipertensión (0,41; 0,34- 0,50, P < 0,001), e insuficiencia cardiaca (0,57, 0,34- 0,96; P = 0.033). Los resultados fueron similares en aquellos pacientes con y sin T2D (expuesto versus control) excepto en la FA incidental que se redujo en el grupo T2D. La práctica de BS se asoció con una reducción del riesgo de insuficiencia cardiaca y mortalidad.
Sections du résumé
BACKGROUND
Cohort studies have shown that bariatric surgery may reduce the incidence of and mortality from cardiovascular disease (CVD), but studies using real-world data are limited. This study examined the impact of bariatric surgery on incident CVD, hypertension and atrial fibrillation, and all-cause mortality.
METHODS
A retrospective, matched, controlled cohort study of The Health Improvement Network primary care database (from 1 January 1990 to 31 January 2018) was performed (approximately 6 per cent of the UK population). Adults with a BMI of 30 kg/m
RESULTS
A total of 5170 exposed and 9995 control participants were included; their mean(s.d.) age was 45·3(10·5) years and 21·5 per cent (3265 of 15 165 participants) had T2DM. Median follow-up was 3·9 (i.q.r. 1·8- 6·4) years. Mean(s.d.) percentage weight loss was 20·0(13·2) and 0·8(9·5) per cent in exposed and control groups respectively. Overall, bariatric surgery was not associated with a significantly lower CVD risk (adjusted hazard ratio (HR) 0·80; 95 per cent c.i. 0·62 to 1·02; P = 0·074). Only in the gastric bypass group was a significant impact on CVD observed (HR 0·53, 0·34 to 0·81; P = 0·003). Bariatric surgery was associated with significant reduction in all-cause mortality (adjusted HR 0·70, 0·55 to 0·89; P = 0·004), hypertension (adjusted HR 0·41, 0·34 to 0·50; P < 0·001) and heart failure (adjusted HR 0·57, 0·34 to 0·96; P = 0·033). Outcomes were similar in patients with and those without T2DM (exposed versus controls), except for incident atrial fibrillation, which was reduced in the T2DM group.
CONCLUSION
Bariatric surgery is associated with a reduced risk of hypertension, heart failure and mortality, compared with routine care. Gastric bypass was associated with reduced risk of CVD compared to routine care.
ANTECEDENTES
Estudios de cohortes han mostrado que la cirugía bariátrica puede reducir la incidencia de enfermedad cardiovascular (cardiovascular disease, CVD) y la mortalidad, pero los estudios basados en datos del mundo real son limitados. Este estudio examinaba el impacto de la cirugía bariátrica (bariatric surgery, BS) en la incidencia de CVD, hipertensión, fibrilación auricular (FA) y mortalidad por cualquier causa. MÉTODOS: Se realizó un estudio retrospectivo de cohortes, controlado por emparejamiento, a partir de la base de datos de atención primaria del The Health Improvement Network (THIN) (1/1/1990 y 31/1/2018) (aproximadamente el 6% de la población del Reino Unido UK). En el grupo de exposición, se incluyeron adultos con un índice de masa corporal (IMC) ≥ 30 kg/m
RESULTADOS
Se incluyeron un total de 5.170 sujetos expuestos y 9.995 participantes controles. La edad media (DE) fue 45,3 (10,5) años, 21,5% (n = 3.265) tenían T2D. La mediana de seguimiento era de 3,9 años (rango intercuartílico 1,8- 6,4). La media ± desviación estándar del % de pérdida de peso fue del 20,0 ± 13,2% en el grupo BS versus 0,8 ± 9,5% en los grupos control. Globalmente, la BS no se asoció con una CVD significativamente más baja (cociente de riesgos instantáneos ajustados, adjusted hazard ratio, HR 0,80; i.c. del 0,62- 1,02, P = 0,074). Solo en el grupo del bypass gástrico se observó un impacto significativo en CVD (0,53, 0,34- 0,81, P = 0,003). BS se asoció con una reducción significativa en la mortalidad de cualquier causa (0,70; i.c. Del 95% 0,55- 0,89, P = 0,004), hipertensión (0,41; 0,34- 0,50, P < 0,001), e insuficiencia cardiaca (0,57, 0,34- 0,96; P = 0.033). Los resultados fueron similares en aquellos pacientes con y sin T2D (expuesto versus control) excepto en la FA incidental que se redujo en el grupo T2D.
CONCLUSIONES
La práctica de BS se asoció con una reducción del riesgo de insuficiencia cardiaca y mortalidad.
Autres résumés
Type: Publisher
(spa)
Estudios de cohortes han mostrado que la cirugía bariátrica puede reducir la incidencia de enfermedad cardiovascular (cardiovascular disease, CVD) y la mortalidad, pero los estudios basados en datos del mundo real son limitados. Este estudio examinaba el impacto de la cirugía bariátrica (bariatric surgery, BS) en la incidencia de CVD, hipertensión, fibrilación auricular (FA) y mortalidad por cualquier causa. MÉTODOS: Se realizó un estudio retrospectivo de cohortes, controlado por emparejamiento, a partir de la base de datos de atención primaria del The Health Improvement Network (THIN) (1/1/1990 y 31/1/2018) (aproximadamente el 6% de la población del Reino Unido UK). En el grupo de exposición, se incluyeron adultos con un índice de masa corporal (IMC) ≥ 30 kg/m
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
432-442Subventions
Organisme : Department of Health
ID : CS-2013-13-029
Pays : United Kingdom
Organisme : National Institute for Health Research
ID : CS-2013-13-029
Pays : International
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2020 BJS Society Ltd Published by John Wiley & Sons Ltd.
Références
WHO. Cardiovascular Diseases (CVDs); 2017. http://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) [accessed 8 October 2018].
Bhatnagar P, Wickramasinghe K, Williams J, Rayner M, Townsend N. The epidemiology of cardiovascular disease in the UK 2014. Heart 2015; 101: 1182-1189.
Office for National Statistics. Death Registrations Summary Tables - England and Wales; 2018. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/deathregistrationssummarytablesenglandandwalesreferencetables [accessed 8 October 2018].
Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009; 53: 1925-1932.
Caleyachetty R, Thomas GN, Toulis KA, Mohammed N, Gokhale KM, Balachandran K et al. Metabolically healthy obese and incident cardiovascular disease events among 3·5 million men and women. J Am Coll Cardiol 2017; 70: 1429-1437.
Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9: 88.
Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011; 34: 1481-1486.
Heneghan HM, Meron-Eldar S, Brethauer SA, Schauer PR, Young JB. Effect of bariatric surgery on cardiovascular risk profile. Am J Cardiol 2011; 108: 1499-1507.
Jamaly S, Carlsson L, Peltonen M, Jacobson P, Sjöström L, Karason K. Bariatric surgery and the risk of new-onset atrial fibrillation in Swedish obese subjects. J Am Coll Cardiol 2016; 68: 2497-2504.
Sjostrom L, Peltonen M, Jacobson P, Sjostrom CD, Karason K, Wedel H et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65.
Major P, Kowalczuk A, Wysocki M, Osadnik S, Pedziwiatr M, Gluszewska A et al. Effects of bariatric surgery on cardiovascular risk factors among morbidly obese patients. Pol Przegl Chir 2017; 89: 41-49.
Schiavon CA, Bersch-Ferreira AC, Santucci EV, Oliveira JD, Torreglosa CR, Bueno PT et al. Effects of bariatric surgery in obese patients with hypertension: the GATEWAY randomized trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension). Circulation 2018; 137: 1132-1142.
Ricci C, Gaeta M, Rausa E, Asti E, Bandera F, Bonavina L. Long-term effects of bariatric surgery on type II diabetes, hypertension and hyperlipidemia: a meta-analysis and meta-regression study with 5-year follow-up. Obes Surg 2015; 25: 397-405.
Benotti PN, Wood GC, Carey DJ, Mehra VC, Mirshahi T, Lent MR et al. Gastric bypass surgery produces a durable reduction in cardiovascular disease risk factors and reduces the long-term risks of congestive heart failure. J Am Heart Assoc 2017; 6: pii: e005126.
Zhou X, Yu J, Li L, Gloy VL, Nordmann A, Tiboni M et al. Effects of bariatric surgery on mortality, cardiovascular events, and cancer outcomes in obese patients: systematic review and meta-analysis. Obes Surg 2016; 26: 2590-2601.
Fisher DP, Johnson E, Haneuse S, Arterburn D, Coleman KJ, O'Connor PJ et al. Association between bariatric surgery and macrovascular disease outcomes in patients with type 2 diabetes and severe obesity. JAMA 2018; 320: 1570-1582.
Scott JD, Johnson BL, Blackhurst DW, Bour ES. Does bariatric surgery reduce the risk of major cardiovascular events? A retrospective cohort study of morbidly obese surgical patients. Surg Obes Relat Dis 2013; 9: 32-39.
National Institute for Health and Care Excellence (NICE). Obesity: Identification, Assessment and Management. Clinical Guideline [CG189]; 2014. https://www.nice.org.uk/guidance/cg189 [accessed 8 October 2018].
Miras AD, Kamocka A, Patel D, Dexter S, Finlay I, Hopkins JC et al. Obesity surgery makes patients healthier and more functional: real world results from the United Kingdom National Bariatric Surgery Registry. Surg Obes Relat Dis 2018; 14: 1033-1040.
The Health Improvement Network. THIN Data. https://www.the-health-improvement-network.co.uk [accessed 3 December 2019].
THIN HES Privacy Notice. https://www.iqvia.com/locations/united-kingdom/information-for-members-of-the-public/thin-hes-data [accessed 3 December 2019].
UCL. UCL-London's Global University. https://www.ucl.ac.uk/epidemiology-health-care/node/7035/database [accessed 3 December 2019].
Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 2011; 19: 251-255.
Benson T, Grieve G. Coding and classification schemes. In Principles of Health Interoperability. London: Springer, 2016; 135-154.
Adderley NJ, Nirantharakumar K, Marshall T. Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies. BMJ 2018; 361: k1717.
Daly B, Toulis KA, Thomas N, Gokhale K, Martin J, Webber J et al. Increased risk of ischemic heart disease, hypertension, and type 2 diabetes in women with previous gestational diabetes mellitus, a target group in general practice for preventive interventions: a population-based cohort study. PLoS Med 2018; 15: e1002488.
Subramanian A, Adderley NJ, Tracy A, Taverner T, Hanif W, Toulis KA et al. Risk of incident obstructive sleep apnea among patients with type 2 diabetes. Diabetes Care 2019; 42: 954-963.
Toulis KA, Willis BH, Marshall T, Kumarendran B, Gokhale K, Ghosh S et al. All-cause mortality in patients with diabetes under treatment with dapagliflozin: a population-based, open-cohort study in the health improvement network database. J Clin Endocrinol Metab 2017; 102: 1719-1725.
Maguire A, Blak BT, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Saf 2009; 18: 76-83.
Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 167: 492-499.
Sheibani H, Esmaeili H, Tayefi M, Saberi-Karimian M, Darroudi S, Mouhebati M et al. A comparison of body mass index and percent body fat as predictors of cardiovascular risk factors. Diabetes Metab Syndr 2019; 13: 570-575.
Burke GM, Genuardi M, Shappell H, D'Agostino RB Sr, Magnani JW. Temporal associations between smoking and cardiovascular disease, 1971 to 2006 (from the Framingham Heart Study). Am J Cardiol 2017; 120: 1787-1791.
Townsend P, Phillimore P, Beattie A. Health and Deprivation: Inequality and the North. Croom Helm: Beckenham, 1988.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
Pontiroli AE, Morabito A. Long-term prevention of mortality in morbid obesity through bariatric surgery. A systematic review and meta-analysis of trials performed with gastric banding and gastric bypass. Ann Surg 2011; 253: 484-487.
Berger S, Meyre P, Blum S, Aeschbacher S, Ruegg M, Briel M et al. Bariatric surgery among patients with heart failure: a systematic review and meta-analysis. Open Heart 2018; 5: e000910.
He J, Whelton PK, Appel LJ, Charleston J, Klag MJ. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 2000; 35: 544-549.
Magkos F, Fraterrigo G, Yoshino J, Luecking C, Kirbach K, Kelly SC et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601.
le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006; 243: 108-114.
Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ et al. Cardiovascular outcomes with glucagon- like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 2018; 6: 105-113.
Mingrone G, Guidone C, Iaconelli A, Nanni G, Castagneto M, Panunzi S et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single- centre, randomised controlled trial. Lancet 2015; 386: 964-973.
Schauer PR, Mingrone G, Ikramuddin S, Wolfe B. Clinical outcomes of metabolic surgery: efficacy of glycemic control, weight loss, and remission of diabetes. Diabetes Care 2016; 39: 902-911.
Mohamed I. Mini gastric bypass is a safe and reliable procedure for type 2 diabetes remission/control in patients with BMI 31-40. Gastric bypass procedures including Roux-en-Y gastric bypass (RYGB) and one anastomosis gastric bypass (OAGB)/MGB. 22nd World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders, London, UK. Obes Surg 2017; 27(Suppl 1): 581.
Dixon JB, O'Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008; 299: 316-323.
Sheng B, Truong K, Spitler H, Zhang L, Tong X, Chen L. The long-term effects of bariatric surgery on type 2 diabetes remission, microvascular and macrovascular complications, and mortality: a systematic review and meta-analysis. Obes Surg 2017; 27: 2724-2732.
Guest JF, Fuller GW, Vowden P. Diabetic foot ulcer management in clinical practice in the UK: costs and outcomes. Int Wound J 2018; 15: 43-52.
Sharma M, Nazareth I, Petersen I. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. BMJ Open 2016; 6: e010210.